Amarantus CEO publishes new blog post titled "Transformational Funding Positions Amarantus Heading into 2014 Milestones." Mr. Commissiong writes about the new opportunities the Company has due to key additional funding.  http://bit.ly/1ndl9Vx

Head football coach at Westborough High School, Mark Ellis, discusses with the Boston Globe the unsettling truth that every year less and less players will be on his team due to the growing fear of concussions. Read entire story here: http://b.globe.com/1mVo1Gs

Sports-related concussions have been in the spotlight recently and the MLB has taken notice. The league is working to improve player safety, the latest step being to restrict home plate collisions. http://es.pn/1mVnNyY

The American Academy of Neurology compared 10 of the most widely used football helmets in drop tests designed to measure the kinds of forces that are most likely to result in concussion. http://lat.ms/1mIOvLi

In his new blog, “Q1-2014: The Maturation of Amarantus,” President and CEO Gerald Commissiong writes about the progress the Company has made recently. In addition to the expansion of Amarantus’ pipeline, the Company has strengthened its management team and has met a number of key milestones. Read the full blog here: http://bit.ly/1dpjgLo

Amarantus closes Warrant Solicitation; enters into $20 million purchase agreement with Lincoln Park Capital Fund, LLC. CEO Gerald Commissiong states "The capital raised through our Warrant Solicitation  and the access to capital from LPC increases our flexibility to achieve a number of key milestones for the Company..." http://bit.ly/1nctyZo

Amarantus enters into exclusive option agreement with the University of Massachusetts to license the University’s method of use intellectual property surrounding the use of MANF and CDNF for the treatment of antibiotic-induced ototoxicity. CEO Gerald Commissiong states "Adding the orphan indication antibiotic-induced ototoxicity to our growing list of orphan applications for MANF is a tremendous step forward for the Company..." http://bit.ly/1e5lOP7

Amarantus outlines research collaboration strategy for MANF and expands its list of select scientific publications for MANF on Company website to forty two. Updated information focusing on the therapeutic potential for MANF in retinal degeneration from the University of Miami's Bascom Eye Institute as well as a new abstract from researchers at Buck Institute on Aging available here: http://bit.ly/1dTVcR8

In today's Forbes article titled "Crowdfunding Health Innovation: Disruptive Companies And Funders Meet To Change Health Delivery," Amarantus CEO Gerald Commissiong speaks about the opportunities small-cap and private companies were given at The 7th Annual OneMed Forum. http://onforb.es/1mD8Rp5

Amarantus appoints Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Gerald E. Commissiong stated "I am pleased to welcome Mr. Segal and Ms. Clark to Amarantus at this key time in our buisness life-cycle.." http://bit.ly/1doWxzb